Name (Synonyms) | Correlation | |
---|---|---|
drug1030 | HLCM051 Wiki | 1.00 |
drug2319 | Standard of Care Wiki | 0.20 |
Name (Synonyms) | Correlation | |
---|---|---|
D013577 | Syndrome NIH | 0.11 |
D055371 | Acute Lung Injury NIH | 0.10 |
D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.10 |
D012128 | Respiratory Distress Syndrome, Adult NIH | 0.09 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
Study to assess the safety and efficacy of STI-5656 (Abivertinib Maleate) plus SOC versus SOC in subjects hospitalized with COVID-19
Description: Proportion of subjects alive and free of respiratory failure at Day 14
Measure: Proportion of subjects alive and free of respiratory failure at Day 14 Time: Randomization to Day 14Description: Types, frequencies, and severities of adverse events and their relationships to STI-5656
Measure: Incidence of treatment-emergent adverse events (safety and tolerability of STI-5656) Time: Randomization through study completion to 90 daysDescription: Proportion of subjects alive and free of respiratory failure at Day 28
Measure: Proportion of subjects alive and free of respiratory failure at Day 28 Time: Randomization to Day 28Description: Change in clinical status on a 0-8-point ordinal scale (lower score means better outcome; 0=uninfected, 8=dead)
Measure: Change in clinical status Time: Randomization to Day 7, Day 14, and Day 28Description: Proportion of subjects alive and discharged from ICU at Days 14 and 28
Measure: Discharge from ICU Time: Randomization to Day 14 and Day 28Description: Time from randomization to first occurrence of respiratory failure or death on study due to any cause up to Day 28
Measure: Time to respiratory failure or death Time: Randomization to Day 28